stoxline Quote Chart Rank Option Currency Glossary
  
HCW Biologics Inc. (HCWB)
8.405  -0.295 (-3.39%)    05-22 15:33
Open: 8.7
High: 8.8205
Volume: 74,003
  
Pre. Close: 8.7
Low: 8.3
Market Cap: 18(M)
Technical analysis
2025-05-22 3:17:53 PM
Short term     
Mid term     
Targets 6-month :  15.07 1-year :  20.79
Resists First :  12.91 Second :  17.79
Pivot price 7.85
Supports First :  5 Second :  4.16
MAs MA(5) :  8.76 MA(20) :  7.76
MA(100) :  12.2 MA(250) :  19.3
MACD MACD :  -0.2 Signal :  -0.4
%K %D K(14,3) :  29.3 D(3) :  29.8
RSI RSI(14): 49.8
52-week High :  100.8 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HCWB ] has closed below upper band by 38.9%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.22 - 9.27 9.27 - 9.3
Low: 8.43 - 8.49 8.49 - 8.54
Close: 8.62 - 8.71 8.71 - 8.78
Company Description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Headline News

Tue, 20 May 2025
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biologics Inc (HCWB) - GuruFocus

Fri, 16 May 2025
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus

Thu, 15 May 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewswire

Thu, 15 May 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - Stock Titan

Tue, 13 May 2025
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire

Tue, 13 May 2025
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 400520 (%)
Held by Institutions 39.7 (%)
Shares Short 10 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.83e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 129.6 %
Return on Equity (ttm) -62.8 %
Qtrly Rev. Growth 2.57e+006 %
Gross Profit (p.s.) -81.63
Sales Per Share -1043.46
EBITDA (p.s.) 1.11558e+006
Qtrly Earnings Growth -30.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -1.19
Stock Dividends
Dividend 0
Forward Dividend 6920
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android